Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344200 | 0.87 | PTGS2 (0.44) | PTGS2F10 | |
| SCHEMBL2337506 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL2340431 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HPGD | |
| SCHEMBL2342728 | 0.79 | HPGD (0.42) | ALDH1A1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL2350173 | 0.77 | HPGD (0.38) | HPGDKMT2A | |
| SCHEMBL1515215 | 0.76 | LMNA (0.47) | ALDH1A1HPGDKDM4EKMT2ATSHR | |
| SCHEMBL12280261 | 0.75 | PIK3CA (0.43) | ALDH1A1HPGDKDM4EKMT2APTGS2 | |
| SCHEMBL2342841 | 0.72 | SLC6A2 (0.40) | HPGD | |
| SCHEMBL16570287 | 0.72 | SLC6A2 (0.40) | — | |
| SCHEMBL85673 | 0.71 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4EKMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | ALDH1A1 1378/4885HPGD 2840/4885KDM4E 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.